Brief: Regulus Therapeutics Announces Completion Of Enrollment In First Cohort Of Phase 1B Multiple-Ascending Dose Clinical Trial Of RGLS8429
12/04/2023 21:26
April 12 (Reuters) - Regulus Therapeutics Inc RGLS.O :
* REGULUS THERAPEUTICS ANNOUNCES COMPLETION OF ENROLLMENT IN
FIRST
COHORT OF PHASE 1B MULTIPLE-ASCENDING DOSE (MAD) CLINICAL TRIAL
OF RGLS8429 FOR THE TREATMENT OF PATIENTS WITH AUTOSOMAL
DOMINANT POLYCYSTIC KIDNEY DISEASE (ADPKD)
* REGULUS THERAPEUTICS INC- EXPECTS TO BEGIN DOSING SECOND
COHORT
FOLLOWING REVIEW OF ALL AVAILABLE COHORT 1 SAFETY DATA, WHICH IS
PLANNED FOR MAY 2023
Source text for Eikon: ID:nPn24WTCJa
Further company coverage: RGLS.O
((Reuters.Brief@thomsonreuters.com;))
Recent news on Regulus Therapeutics
See all newsBrief: Novartis Completes Acquisition Of Regulus Therapeutics
Brief: Novartis Announces Expiration Of Hart-Scott-Rodino Waiting Period Of Regulus Therapeutics Tender Offer
Brief: Novartis Announces Commencement Of Tender Offer To Acquire Regulus Therapeutics
Regulus Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary
Regulus Therapeutics Inc expected to post a loss of 24 cents a share - Earnings Preview